Dr. Remuinan studied Chemistry in Madrid and received his Ph.D. in organic chemistry in 1997 from Universidad de Alcala (Madrid). In that year, he moved to UK for postdoctoral research at Nottingham University to work in total synthesis of natural products. In 2001, he begun his proffesional carreer as Medicinal chemist at pharmaceutical industry (Pharmamar, Ely lilly and GSK). In 2010 he was appointed as Project Leader of both lead generation and lead optimization programs in Global Health Unit at GSK. Dr. Remuinan has authored more than 20 research publications and 15 international patents in tuberculosis.
Dr Raphaël RODRIGUEZ
KLAUS GROHE PRIZE 2022 Discovery of a Druggable Copper-signaling Pathway that Drives Cell Plasticity and Inflammation
Raphaël Rodriguez, PhD, FRSC, is a Research Director at the CNRS and a Senior Principal Investigator at Institut Curie, where he holds the Marie Curie Chair of Chemical Biology. He trained under the mentorships of Sir J. E. Baldwin (Oxford) and Sir S. Balasubramanian (Cambridge) from whom he acquired deep knowledge of chemistry. A key scientific contribution of his has been to discover the prevalent role of d-block metals in the regulation of cell plasticity and the dicovery of a universal metal uptake mechanism mediated by CD44 and hyaluronate. He is a Fellow of the Royal Society of Chemistry and has received various awards, including the Tetrahedron Young Investigator Award, the Prix Lacassagne (Collège de France), and the Grand Prix Charles Defforey (Institut de France). He also is the scientific co-founder of several companies including SideROS and Adrestia Therapeutics.
Prof. Olalla VÁZQUEZ
EFMC PRIZE FOR A YOUNG MEDICINAL CHEMIST OR CHEMICAL BIOLOGIST IN ACADEMIA Chemical Biology Tools for Enlightening Drug Discovery
Benoît Déprez received a degree of pharmaceutical sciences from the school of pharmacy of Lille and a PhD in medicinal chemistry in the Lab of André Tartar at the Institut Pasteur de Lille (1997).With André Tartar, he created the High Throughput Chemistry laboratory of the Institut Pasteur that became in 1997 the chemistry department of Cerep. In 1999, after 3 years spent at Cerep as Head of Chemistry and Site Manager, he was hired by Devgen, a Belgian start-up in Gent (Flanders), where he set up Drug Discovery activities using C.elegans. From 1995 on, he managed several collaborations between biotech or academic labs and pharmaceutical companies (GSK, Merck KGa, Sanofi, Genentech). Benoît Deprez is currently Professor of Medicinal Chemistry at the Faculty of Pharmacy (U. Lille) and founder and director of Inserm Lab U761, now U1177 based at the Institut Pasteur de Lille and the Faculty of pharmacy. His research interests primarily focus on early drug discovery : target validation, medicinal chemistry and pharmacokinetic. Areas explored by his team are infectious diseases, metabolic diseases, and cancer using a molecular approach and cutting edge screening technologies including high throughput cell imaging. Benoit is correspondent member of the Académie Nationale de Pharmacie. In 2013, he founded APTEEUS with Terence Beghyn, a company focused on personalized drug discovery for rare monogenic diseases. In 2016, APTEEUS was a recipient of Individualized Medecine Award at the Concours Mondial d’Innovation. In June 2018, he was appointed as Scientific Advisor to the Board of the Institut Pasteur de Lille, then, in March 2019, as Scientific Director of the Institut Pasteur de Lille. Three candidate drugs discovered in his lab are currently licenced for clinical development to biotech and pharmaceutical companies.
Prof. Eric MISKA
New Biology and Therapeutic Approaches from RNA Shape and Modification
Prof Eric Miska (h=68, >43,000 citations on Google Scholar; >130 papers; 3 patents) is a molecular cell biologist with a focus on gene regulation, RNA and epigenetics. Eric studied mathematics, physics and biology at Heidelberg, Berlin and Mainz and received a BA in Biochemistry from Trinity College, Dublin, in 1996. He received his PhD in Pathology from the University of Cambridge, UK, in 2000, studying epigenetics with Prof Tony Kouzarides. He was a postdoctoral fellow in the laboratory of Nobel laureate (2002) Bob Horvitz at the MIT, Cambridge, MA, USA from 2000 to 2004, where he did pioneering work on regulatory RNA. Prof Miska started his independent research group at the Gurdon Institute at the University of Cambridge in 2005. Now he is the Herchel Smith Professor of Molecular Genetics and Deputy Director of the Gurdon Institute at the University of Cambridge and a Fellow of St. John’s College. Eric is also an associated faculty member at the Wellcome Trust Sanger Institute. Prof Miska was an EMBO Young Investigator, and is a full member of EMBO since 2012. He was the 2013 recipient of the Hooke Medal awarded by the British Society of Cell Biology. Prof Miska is a Wellcome Trust Senior Investigator, and has been the PI of a Cancer Research UK Programme grant since 2005. He has also been awarded grants from the ERC, HFSP, BBSRC and Leverhulme Trust. So far, he has given over 200 invited lectures, has organised four international conferences and run workshops for EMBO, NIH and HHMI. He is also a Founder and Director of a £20 million University of Cambridge spin-out, STORM Therapeutics Ltd.
Prof. Sarah E. REISMAN
Necessity is the Mother of Invention: Natural Products and the Chemistry They Inspire
CALIFORNIA INSTITUTE OF TECHNOLOGY Pasadena, United States
Professor Sarah Reisman earned a BA in Chemistry from Connecticut College in New London, CT and
her Ph.D. in chemistry from Yale University, conducting research with Prof. John L. Wood in the area of
natural product total synthesis. As an NIH post-doctoral fellow, Sarah pursued studies in the field of
asymmetric catalysis working with Prof. Eric Jacobsen at Harvard University. In 2008, Sarah joined the
faculty at the California Institute of Technology where she is now the Bren Professor of Chemistry.
Research in the Reisman laboratory seeks to advance the science of chemical synthesis, through
synergistic contributions in both strategy design for natural product synthesis and reaction
development. Reisman is recognized as a leader in the area of natural product synthesis, where her
group has contributed new strategy-driven approaches a number of complex highly oxidized natural
products. In addition to her program in natural product synthesis, Reisman has made impactful
contributions to the rapidly advancing field of Ni-catalysis, with an emphasis on asymmetric reductive
cross-coupling reactions. Reisman is an editorial board member at Organic Syntheses and an
associate editor for the Journal of the American Chemical Society. Reisman has been recognized with
a number of awards for teaching and research, including an Alfred P. Sloan Research Fellowship, a
Cottrell Scholar Award, the Arthur C. Cope Scholar Award, the Tetrahedron Young Investigator Award,
the Margaret Faul Women in Chemistry award, and the ACS Elias J. Corey Award.
Professor Outi Vaarala, M.D., Ph.D. is a medical doctor (University of Helsinki) and has a PhD in immunology. Outi Vaarala was appointed as a Professor of Pediatric Immunology, Linkoping University, Sweden, in 2000, and as a Professor of Autoimmune Diseases, Lund University, Sweden, in 2015.
As of June 2020, she was appointed as Senior Vice President for Research and Development of the Orion Group and is a member of the Orion Executive Management Board. Vaarala has held the position of Vice President, Oncology Research in Orion’s Research and Development as of June 2019. Prior to Orion, Vaarala led drug discovery and development from target identification to clinical Phase 2 studies in Respiratory Inflammation and Autoimmunity therapy area, first at AstraZeneca, Sweden, and later at Medimmune/AstraZeneca, USA.
Outi Vaarala has excellent background and experience from various leadership positions in Research and Development in the international pharmaceutical industry as well as a long experience of immunology and remarkable career in the academy. She has published more than 200 peer-reviewed scientific articles in internationally renowned scientific journals.
Current key positions of trust: Member of the Board of Directors: Tampere University Foundation, Finland 2021- and Member of Steering Group, National Drug Discovery Development Platform, Karolinska Institutet, Stockholm, Sweden 2022-. Former key positions of trust: 2005-2014 Permanent expert at the European Medicines Agency (EMA).
Dr Louise WALPORT
De Novo Cyclic Peptides as Chemical Tools to Explore Epigenetic Regulation
UNIVERSITY OF CALIFORNIA San Francisco, United States
Michelle Arkin is Professor and Chair of Pharmaceutical Chemistry at the University of California, San Francisco and co-director of the Small Molecule Discovery Center. Her lab focuses on developing chemical probes and drug leads for novel targets, with a particular interest in protein-protein interactions and protein-degradation networks. Prior to UCSF, Michelle worked at Sunesis Pharmaceuticals, where she helped discover protein-protein interaction inhibitors for IL-2 and LFA-1 (lifitigrast, marketed by Novartis). Michelle held an NSF predoctoral fellowship at Caltech and Damon Runyon Cancer Research postdoctoral fellowship at Genentech. She is a cofounder of Ambagon and Elgia Therapeutics.
Dr Andrea BECCARI
Embrace Complexity: in Silico Polypharmacological Profiling to Repurpose Medicines and Design New Drugs
Andrea started his carrier as drug designer in academia before joining Organon, a global pharmaceutical company in the Netherlands. He earned his degree in MD, Computational Chemistry from University of Catania and then in Medicinal and Pharmaceutical Chemistry from University of Parma.
Andrea leads the Business Unit R&D Platforms and Services of Dompé Pharmaceuticals and is the coordinator of Dompé EXSCALATE research and development platform. He has also been responsible for the Joint Bioinformatics Groups at the IBP Institute of the National Research Council of Italy since 2015. Co-Funder of the Avicenna Alliance for European in-silico medicine awareness. Since 2022 member of the PRACE Industrial Advisory Committee supporting HPC development and adoption in Europe.
During the past twenty years, Andrea has been responsible for developing proprietary computational tools such as LiGen™, GPCRBase™, and LigandBase™ and most recently was the Principal Investigator of two EU-funded projects -- EXSCALATE4COV and LIGATE.
Author of more than 30 peer-reviewed scientific publications and co-inventor of more than 10 patents.
Andrea lead to the development of two drugs currently in clinical trials
Dr Amy BITTNER MCCRACKEN
Inhibiting the MYC Oncogene through Cell Active Max-E47 (ME-47)
Amy Bittner McCracken began her career at Merck Sharpe and Dohme in 2004 as a Staff Chemist within Discovery Chemistry organization after completing her bachelor’s degree at Bucknell University in Lewisburg, PA. Early in her career, Amy was given the opportunity to pursue graduate studies as part of the selective Merck Doctoral Program. She obtained her Ph.D. at Princeton University under the supervision of Prof. Erik Sorensen. Since receiving her Ph.D., Amy has impacted pipeline programs that spanned several therapeutic areas from cardiovascular to oncology. She has worked across multiple modalities from traditional small molecule to large peptide projects. In addition, Dr. Bittner is adept at applying of high throughput experimentation (HTE) to solve synthetic and medicinal chemistry problems. Amy is currently an Associate Principal Scientist in the Discovery Chemistry NJ.
Prof. Jeffrey BODE
Molecular Vending Machines for the On-Demand Synthesis of Drug-Like Molecules
In 2012, Pascal Bonnet joined the Institute of Organic and Analytical Chemistry (ICOA) from the University of Orléans (France) as full professor. He set up the team “Structural Bioinformatics and Chemoinformatics”, which develops and integrates novel computational methods for drug discovery. His research interests also focus on the development of an integrative in silico platform for kinase research. In 2016, he was appointed director of the ICOA and since 2021 he was elected vice president for research of the University of Orléans. After completing his PhD in 2001 at the University of Orléans and at the University of Barcelona (Spain), he moved to a postdoctoral position at the University of Manchester, UK. As a scientist, he joined Janssen-Cilag in France and then Janssen-Pharmaceutica in Belgium in 2003. He was involved in several drug discovery projects mainly in the oncology therapeutic area. Promoted Principal Scientist in 2010, he was leading the Kinase Platform at Janssen. He contributed to the development of a clinical drug candidate, erdafitinib, a FGFR kinase inhibitor discovered by FBDD approved in April 2019 against bladder cancer.
Dr Marco BORGOGNO
Discovery of Selective NKCC1 Inhibitors for the Treatment of Core Symptoms in Autism, Down Syndrome, and Brain Disorders with Defective NKCC1/KCC2 Ratio
Dr. Marco Borgogno is a team leader in discovery chemistry and board member at IAMA Therapeutics. At IAMA he leads the company’s medicinal chemistry programs and advanced preclinical drug-development and manufacturing. Marco obtained a MSc in Medical and Pharmaceutical Biotechnology from the university of Genova. He then obtained a Ph.D. in biotechnological and pharmaceutical sciences from the University of Bologna working in the lab of Dr. Marco De Vivo at IIT Genova, where he discovered a novel class of selective NKCC1 inhibitors for the treatment of Down syndrome and autism. He then pursued its work on CNS drug discovery as a postdoctoral researcher in Dr. De Vivo’s lab, where he was responsible of different projects aiming at the targeting of cation-chloride cotransporters, and delivered several lead compounds for the treatment of different neurological conditions. He then joined IAMA Therapeutics to lead the medicinal chemistry team towards the early and late-stage development of the new compounds to treat autism and other brain disorders.
Dr Andreas BRUNSCHWEIGER
A DNA Barcode with Enhanced Chemical Stability for DNA-encoded Library Design
Andreas Brunschweiger studied pharmacy at the University of Kiel (Germany), and obtained
his PhD in the group of Prof. Christa Müller at the University of Bonn (Germany) in 2007. He
stayed as postdoctoral researcher in Christa Müller´s group to develop small molecule
inhibitors for targets associated with neurodegenerative diseases in a collaboration project with
UCB Pharma. Then, he joined Prof. Jonathan Hall's research group at the ETH Zurich
(Switzerland) in 2010. There, he was involved in the design and synthesis of chemical biology
tools to study microRNA biology, and the design and synthesis of short oligonucleotides as
microRNA inhibitors. In 2013 he took up his present position as a group leader at the
Department of Chemistry and Chemical Biology of the TU Dortmund University. His current
research interests include the development of new synthesis and encoding strategies that
allow for expanding the chemical space of DNA-encoded small molecule screening libraries,
computational tools that support screening library design, and development of protein-protein
Prof. Youngjoo BYUN
Medicinal Chemistry in the Development of Molecular Imaging Probes Targeting Prostate-Specific Membrane Antigen
Youngjoo Byun graduated from Seoul National University (Seoul, South Korea) with BS and MS degrees. He received his PhD from Ohio State University College of Pharmacy (Columbus, USA) in 2006 under the supervision of Dr. Werner Tjarks. Before joining OSU's graduate program, he worked as a Research Scientist in the Drug Discovery Division of AmorePacific Corporation from 1996 to 2001. He was a postdoctoral fellow and instructor at Johns Hopkins University (Baltimore, USA) under the guidance of Dr. Martin G. Pomper with a project to develop PSMA-based imaging probes. In 2011, he joined a faculty at the College of Pharmacy, Korea University (Sejong, South Korea). He is currently Professor at the KU College of Pharmacy and Director of the Institute of Pharmaceutical Science and Translational Research. His research interests include the discovery of new small molecules targeting PSMA and hepsin, cytokine inhibitors targeting interleukin-33 and thymic stromal lymphopoietin, and anti-biofilm inhibitors targeting LasR and RhlR.
Dr Sébastien CAMPAGNE
Fundamental Basis for SMN2 Specific Splicing Correction by Small Molecules and Bulge Repair Mechanism
Lisa Candish received her PhD from Monash University, Australia, under the supervision of Prof. David W. Lupton in 2014. In the same year she relocated to Germany as an Alexander von Humboldt fellow to carry out postdoctoral studies at the Westfälische Wilhelms-Universität Münster with Prof. Frank Glorius. Since 2017, she has been working in Drug Discovery Sciences for Bayer AG, Wuppertal, as a laboratory head in medicinal chemistry. In addition, she leads the department's photochemistry laboratory.
Prof. Connor COLEY
A Perspective on AI and Automation for the Medicinal Chemistry Lab
Charlotte is Professor of Structural Bioinformatics in the Department of Statistics at the University of Oxford and Chief Scientist of Biologics AI at Exscientia. She is also a co-director of the Systems Approaches to Biomedical Research Centre for Doctoral Training which she founded in 2009.
She served on SAGE, the UK Government’s Scientific Advisory Group for Emergencies, during the COVID-19 pandemic and acted as UK Research and Innovation’s COVID-19 Response Director. She has held numerous senior roles at the University of Oxford and until recently was the Deputy Executive Chair of the UK’s Engineering and Physical Sciences Research Council.
At Oxford, Charlotte leads the Oxford Protein Informatics Group (OPIG), who work on diverse problems across immunoinformatics, protein structure and small molecule drug discovery; using statistics, AI and computation to generate biological and medical insight.
Her work focuses on the development of novel algorithms, tools and databases that are openly available to the community. These tools are widely used web resources and are also part of several Pharma drug discovery pipelines. Charlotte is on several advisory boards and has consulted extensively with industry. She has set up a consulting arm within her own research group as a way of promoting industrial interaction and use of the group’s software tools.
Charlotte completed a chemistry degree at Oxford followed by a PhD in Bioinformatics at the University of Cambridge and a 2 year Wellcome Fellowship at UCLA.
Dr Lourdes ENCINAS
Novel Tetrazole Inhibitor of Mycobacterium Tuberculosis Tryptophan Synthase
Lourdes received her B.S. in Chemistry from the University of Basque Country (Spain) in 2003, and her Ph.D. in Chemistry from the Autonoma University of Madrid (Spain) in 2008. Since 2008, she has been working within GSK, mostly on the development of new drugs against tuberculosis. At GSK, she has been involved in several projects; both target-based and phenotypic and in different phases, some in collaborations like a portfolio with Dundee University or a Wellcome Trust sponsored programme. In Nov 2019, she moved to work at Infectious Diseases & Public Health Institute in China, supporting public-private partnerships, like Tsinghua University-GSK postdoctoral Fellowship program. Currently, she serves as Chief of Staff in Global Health Medicines R&D Unit. She is experienced in medicinal chemistry, tuberculosis, drug discovery & pre-clinical research.
Mr Lluc FARRERA SOLER
EFMC-YMCS Prize 2021
A Mating Mechanism to Generate Diversity for the Darwinian Selection of DNA-encoded Synthetic Molecules
Lluc Farrera Soler has a chemistry degree from the University of Barcelona (2014). Supported by an Alfred Werner Scholarship (SCS Foundation), in 2015 he carried out a MSc in Chemical Biology from the NCCR Chemical Biology (a collaboration between the University of Geneva and the EPFL). He later pursued his studies with a PhD in the laboratory of Prof. Nicolas Winssinger (UNIGE) working on the development and application of PNA-encoded libraries both for drug discovery and SARS-CoV-2 epitope mapping. In 2022 he started a post-doc in peptide engineering and diagnostic assay development in a collaborative project between the laboratory of Prof. Christian Heinis (EPFL) and Bühlmann Laboratories.
Dr Yann FORICHER
Targeting RNA with Small Molecules, A New Therapeutic Strategy
Dr Yann Foricher, after joining Sanofi-Aventis as medicinal chemist at Strasbourg in 2004, then moved to Paris in 2011 to work in Oncology Business Division as MedChem team leader and project leader. Since 2017, he has been a medicinal chemist section head in Integrated Drug Discovery Platform. From 2004 to now, he has worked on different projects (target validation with tool compound, hit to lead and lead to candidate) in neuroscience, diabetes, immuno-inflammation & oncology therapeutic areas. Following a chemistry engineer school ENSCMu in France, he obtained his PhD with Prof John Mann on Synthesis of Huperzine A skeleton (University of Reading & at Queen’s University of Belfast - UK) and moved to a postdoctoral research position with Prof Jonathan Clayden (University of Manchester - UK). Before joining Sanofi, he worked as process chemist for DSM Nutritional Products (Switzerland, ex-Roche Vitamins) on vitamin E process.
Dr David FREEMAN
Discovery of KB-0742, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of CDK9/Cyclin T1 for MYC-Dependent Cancers
David B. Freeman is an Associate Director of Chemical Biology at Kronos Bio, Inc. where he leads Small Molecule Microarray (SMM) screening and chemical tool development efforts. Dave obtained a B.S. in Chemistry from University of California, Santa Barbara before completing his doctoral studies focused on the total synthesis of natural products with Professor John Wood at Colorado State University. He then completed post-doctoral training with Corey Stephenson at Boston University, after which, he served in the US Army, Public Health Command, where he managed a molecular diagnostics lab charged with monitoring endemic diseases in the southern US. After serving, Dave returned to his passion for oncology small molecule drug development and worked with Angela Koehler at the Koch Institute for Integrative Cancer Research at MIT. He then joined Kronos Bio, Inc. as its first employee where he spearheaded medicinal chemistry efforts leading to the discovery of KB-0742, a highly selective, orally bioavailable small molecule CDK9 inhibitor.
Dr Marta FRIGOLE-VIVAS
Leveraging Biomolecular Condensates for Drug Discovery
Marta Frigolé-Vivas, PhD
Marta Frigolé-Vivas is a senior scientist at Dewpoint Therapeutics.
She has a background in medicinal chemistry and condensate biology. She is passionate about leveraging condensate biology to develop novel drugs for currently unmet medical needs.
She completed her PhD at the IRB Barcelona on the use of small molecules to modulate the function of intrinsically disordered proteins (IDPs), which are not amenable to structure-based drug discovery methods. Tuning the propensity of IDPs to form condensates emerged as a promising strategy.
Amanda L. Garner is a tenured Associate Professor in the Department of Medicinal Chemistry at the University of Michigan. She received her Ph.D. in Chemistry from the University of Pittsburgh and completed NIH-funded postdoctoral studies at The Scripps Research Institute in La Jolla, California. Dr. Garner’s independent research integrates chemical biology, medicinal chemistry, and molecular and cellular biology approaches for early-stage drug discovery efforts with a primary focus on validating new therapeutic targets in RNA biology.
Prof. Matthew GAUNT
New Synthetic Chemistry to Probe the Biology of Modified Nucleic Acids
Matthias Gehringer studied chemistry at the Karlsruhe Institute of Technology (KIT), the Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM), and the University of Heidelberg. He obtained his Ph.D. from the University of Tübingen where he worked on reversible and irreversible inhibitors of the protein kinase JAK3. As a postdoc at the Swiss Federal Institute of Technology (ETH) Zürich, he focused on the total synthesis of mycolactones and on targeted antibiotic–protein conjugates. In 2019, he was appointed Assistant Professor for Medicinal Chemistry at the Institute of Pharmaceutical Sciences, University of Tübingen. Since 2020, he has been an associate PI in the Cluster of Excellence "Image Guided and Functionally Instructed Tumor Therapies (iFIT)" at the University Hospital and the Faculty of Medicine, University of Tübingen. His research in the areas of medicinal chemistry and chemical biology is mainly dedicated to covalent protein kinase inhibitors and novel covalent targeting approaches.
Dr Carmen GIL
Searching for Drugs against Pandemic Viruses. A Case Study
CENTRO DE INVESTIGACIONES BIOLÓGICAS (CSIC) Read more
Dr Carmen GIL
CENTRO DE INVESTIGACIONES BIOLÓGICAS (CSIC) Madrid, Spain
Carmen Gil received her PhD from Complutense University of Madrid (Spain) in 2001. After a postdoctoral appointment at Bonn University (Germany), she joined the Medicinal Chemistry Institute (CSIC) in 2004 (first as Associate Researcher and since 2007 as Tenured Scientist). In 2014, she cofounded the spin-off Ankar Pharma. Currently, she is Research Scientist at the Biological Research Center (CSIC). Her main expertise is in the drug discovery field. With a strong background in medicinal chemistry, her research is applied with a high content of translational research and focuses on those areas that will have an impact on the treatment of human diseases. Her main research field has been neurodegenerative diseases and more recently, she also focuses her efforts on infectious diseases.
György M. Keserű obtained his Ph.D. at Budapest, Hungary and joined Sanofi heading a chemistry research lab. He moved to Gedeon Richter in 1999 and he was appointed as the Head of Discovery Chemistry in 2007. He contributed to the discovery of the antipsychotic Vraylar® (cariprazine) that has been approved and marketed from 2016 in US and EU. He served as a director general of the Research Centre for Natural Sciences at the Hungarian Academy of Sciences. From 2015 he is heading the Medicinal Chemistry Research Group. György published over 250 papers in medicinal chemistry and drug design and he is a co-inventor in 21 patents. He was awarded by the prestigious Overton and Meyer Award of the European Federation of Medicinal Chemistry and has been elected as Corresponding member of the Hungarian Academy of Sciences.
Prof. Angela KOEHLER
Attenuating Oncogenic Transcription with Small Molecules
MIT KOCH INSTITUTE FOR INTEGRATIVE CANCER RESEARCH Read more
Prof. Angela KOEHLER
MIT KOCH INSTITUTE FOR INTEGRATIVE CANCER RESEARCH Cambridge, United States
Dr Sanja KOSTRUN
Macrolide Inspired Macrocycles as Effective Disruptors of the IL-17A/IL-17RA Interaction
Sanja Koštrun graduated in chemistry and obtained her PhD in the field of computational and physical-organic chemistry. She had several short-term post-doctoral positions at the University of Innsbruck, the University of Florida, Sussex University, and a one year post-doc Humbolt fellowship at the University of Marburg. Sanja has been working in the pharmaceutical, biotech and CRO companies (PLIVA, GlaxoSmithKline, Galapagos, Fidelta and Selvita) for the last 20 years.
Throughout her carrier, she developed broad computational chemistry expertiese as well as medicinal chemistry experience in anti-inflammatory, anti-infective, CNS and oncology therapeutic areas. Sanja was leading a number of projects from hit finding to lead-optimization stage with a range of biological targets from kinases, GPCRs, transporters, epigenetic targets to protein-protein interactions.
Sanja also has extensive experience with beyond the rule of 5 molecules: design, conformational analysis and ADME/PK predictions for the natural products and macrocyclic molecules as well as studies of chameleonic properties and disruption of protein-protein interactions.
Dr Brian LANMAN
Inhibiting KRAS: Strategies, Structures, and Lessons Learned in the Invention of Sotorasib
Brian Lanman is a Director of Research in the Medicinal Chemistry department at Amgen, Inc., based in Thousand Oaks, CA, USA. Brian received his A.B. in Chemistry from Harvard University (1998), where he conducted undergraduate research on the total synthesis of Taxol® with Yoshito Kishi. He subsequently received A.M. (2000) and Ph.D. (2004) degrees from Harvard for research as an NSF fellow on the solid-supported synthesis of tetrahydroisoquinoline antitumor antibiotics in the labs of Andrew Myers. In 2004, he joined Larry Overman’s group at UC Irvine as an NIH postdoctoral fellow, developing methods to access the architecturally complex bis-guanidine natural product palau’amine. Brian joined Amgen’s medicinal chemistry department in 2006, where he has since led chemistry and discovery research efforts in the inflammation, oncology, and cardiovascular therapeutic areas. Most recently, Brian led the medicinal chemistry team that discovered LUMAKRAS®/LUMYKRAS® (sotorasib), Amgen’s first-in-class KRASG12C inhibitor.
Dr María MANEIRO
Antibody-Protac Conjugates: an Approach for Targeted Selective BRD4 Degradation in HER2+ Phenotypes
UNIVERSIDADE DE SANTIAGO DE COMPOSTELA Santiago de Compostela, Spain
Dr Maria Maneiro did her PhD in Organic Chemistry at the Universidade de Santiago de Compostela, under the supervision of Prof. Concepción González-Bello. During her PhD, she worked on the design, synthesis, and biological evaluation of new inhibitors of enzymes involved in metabolism, virulence, and resistance mechanisms of bacteria for the treatment of multi-resistant bacterial infections. After obtaining her PhD degree, in 2018 she joined the group of Prof. Ed Tate at Imperial College London as postdoctoral fellow working on the field of Targeted Protein Degradation. Since April 2021 she is a postdoctoral fellow in González-Bello’s group where she is currently working on the development of innovative approaches to combat bacterial resistance to antibiotics.
Dr Cristina MAYOR-RUIZ
Strategies to Discover Molecular Glue Degraders at Scale
Cristina Mayor-Ruiz obtained her PhD in 2017 at the CNIO (Madrid), unraveling novel mechanisms of resistance to anticancer therapies. In 2018, she joined the group of G. Winter (CeMM, Vienna), where she focused on chemical biology and targeted protein degradation. Since January 2021, she leads her own group at the Institute for Research in Biomedicine (IRB Barcelona). Her research focuses on developing proximity-inducing drugs with therapeutic interest (molecular glues, destabilizers, PROTACs, and beyond), and on tackling biological questions that involve (dys) regulation dynamics of E3 ubiquitin ligases. Dr. Mayor-Ruiz has been honored with national and international awards, such as an ERC Starting grant.
Dr Hannes MIKULA
Next-level Chemical Tools for Ultrafast Bioorthogonal Bond-Cleavage Reactions
Hannes Mikula is a group leader and Assistant Professor of Chemical Biology at the Institute of Applied Synthetic Chemistry at TU Wien (Vienna University of Technology). His research focuses on the development of biocompatible chemical reactions with unmatched performance and unique capabilities. One of the main goals of his group is to design new chemical tools for ultrafast bioorthogonal bond-cleavage and application of this concept in chemical biology and molecular targeting. Hannes trained as a synthetic chemist, finishing his studies in Technical Chemistry in 2008. Following a 1-year career break (parental leave), he finally received his Ph.D. in 2014. Fascinated and inspired by the development and application of bioorthogonal chemistry, he then joined the Center for Systems Biology at the Massachusetts General Hospital & Harvard Medical School as a postdoctoral fellow in the group of Prof. Ralph Weissleder. Hannes returned to TU Wien in 2016 as a young principal investigator and has been leading the research group ‘Molecular Chemistry & Chemical Biology’ since 2018.
Dr Dieter MURI
Tritiation of Pharmaceuticals Via Late Stage C-H Functionalization
ROCHE · PHARMA RESEARCH AND EARLY DEVELOPMENT (PRED) Read more
Dr Dieter MURI
ROCHE · PHARMA RESEARCH AND EARLY DEVELOPMENT (PRED) Basel, Switzerland
Dieter is Senior Principal Scientist in the Isotope Synthesis lab of the Pharma Research and Early Development Unit of Roche in Basel. He is responsible for carbon-14 and tritium labelling of drug and PET tracer candidates for preclinical and clinical studies. One of his research interest includes the development of late-stage tritiations via C-H activation of complex organic molecules and pharmaceuticals. He received his undergraduate and graduate education from the Swiss Federal Institute of Technology (ETH) Zürich and performed postdoctoral studies at Harvard University. He is a member of the advisory board of the Journal of Labelled Compounds and Radiopharmaceuticals and an editorial board member of the Chimia.
Dr Gerhard MÜLLER
The Phosphatase Family: a Widely Neglected Target Space for Small-Molecule Drug Discovery
Dr. Gerhard Müller, Chief Scientific Officer, Anavo Therapeutics
small-molecule drug design around phosphatase modulators
Education and former Profession:
1992: PhD in Organic Chemistry, Technical University of Munich, supervisor: Prof. Horst Kessler
1993-2001: Industry Positions at Glaxo, Verona, Italy; Bayer, Leverkusen, Germany
2001-2003: Head of Medicinal Chemistry at Organon, The Netherlands
2003-2005: Chief Scientific Officer at Axxima Pharmaceuticals, Kinase Platform Company in Munich
2005-2017: Leadership Positions at Proteros Fragments, Mercachem (today Symeres)
2017: co-founder of Gotham Therapeutics, New York-based Biotech in Epitranscriptomics and RNA-targeted drug discovery
2021: co-founder of Anavo Therapeutics, biotech company in phosphatase-targeted drug discovery based in Heidelberg
Dr Frank NARJES
The discovery of the Clinical Candidate AZD0284, a Orally Bioavailable Inverse Agonist of RORG for the Treatment of Psoriasis
Dr. Frank Narjes has over 25 years drug discovery experience gained at Merck, Sharpe & Dohme and AstraZeneca, where he currently is a Senior Principal Scientist in the Department of Medicinal Chemistry. He is passionate about drug discovery and expansion of the druggable target space. In his current role, he leads project teams to deliver clinical candidates with potential across respiratory and autoimmunity diseases. During his career, to advance drug candidates from preclinical to clinical phases, I have worked across several modalities including small molecules, peptides, PROTACs and antibodies and across multiple target classes.
Frank is a coauthor of over 60 publications and coinventor on 40 patents. He did his doctoral thesis in organic chemistry at the University of Hamburg under the supervision of Professor Ernst Schaumann, followed by postdoctoral studies at UC Irvine in the group of Professor Larry Overman.
Prof. Zaneta NIKOLOVSKA-COLESKA
Disrupting hDot1L and MLL Oncofusion Protein Interactions as a Novel Therapeutic Strategy
Mikako Ogawa received PhD degree in 2007 from Graduate School of Pharmaceutical Sciences, Kyoto University (Japan), under the supervision of Prof. Hideo Saji. Thereafter, she worked at National Institute for Longevity Sciences, National Cardio Vascular Center, and Hamamatsu University School of Medicine in Japan. From 2007 to 2009, she worked as a visiting fellow at NCI/NIH, USA. Since 2015, she is a professor of Hokkaido University. She is a molecular imaging chemist, and her research interest is developing new imaging agents, especially for in vivo application. Recently, using the knowledge of in vivo molecular imaging, she is also developing molecular targeted therapeutic agents.
Prof. Defang OUYANG
Opportunity and Challenge of Artificial Intelligence (AI) in Drug Delivery
Prof. Ouyang is associate professor at University of Macau. He has a multidisciplinary background in pharmaceutics & computer modelling, with experience in academia and industry. He obtained his bachelor (2000) and master (2005) in pharmaceutics from Shenyang Pharmaceutical University, China. He completed his PhD in pharmacy at The University of Queensland, Australia, in 2010 and progressed directly to his faculty position (Lecturer in Pharmaceutics, PI) at Aston University (UK). From the end of 2014, he moved to the University of Macau.
Since 2011, he has pioneered the integration of multi-scale modeling, artificial intelligence and big data techniques in the field of drug delivery – “computational pharmaceutics“. He has published 2 books, 5 book chapters and over 70 refereed SCI journal papers. He held 6 approved patents, which had been used in medicinal products. He edited the first book (John Wiley & Sons Inc., 2015) in this research area. He is invited to be the Editors-in-Chief of (Springer Nature) and associate editor of . He also serves as the editorial board or scientific advisor of , , and . He is establishing the first global artificial intelligence (AI)-based formulation platform (FormulationAI). He successfully trained 4 PhD and 25 master.
His research focused on computational pharmaceutics, including:
• Artificial intelligence (AI) of pharmaceutical formulations: to build the database of pharmaceutical formulations and predict pharmaceutical formulations by machine learning approaches;
• Multi-scale modeling in drug delivery: to integrate quantum mechanics (QM), molecular dynamics (MD) and physiologically based pharmacokinetic (PBPK) modeling into drug delivery systems;
• Pharmacoinformatics: big data analysis of pharmaceutical information from the literature, patent, clinical trial and marketed products.
Dr Alex PAUTSCH
Chemical Probes and How to Find Them
BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Read more
Dr Alex PAUTSCH
BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Biberach, Germany
Dr. Alexander Pautsch is a senior principal scientist at Boehringer Ingelheim (BI). He studied chemistry at the universities of Freiburg, Germany and Massachusetts, USA. For his Ph.D. he conducted research with Prof. Georg E. Schulz, Freiburg, working on the structural biology of bacterial membrane proteins and anti-viral drug targets. As a post-doctoral fellow at BI he stayed in the field of protein crystallography, focusing initially on protein kinases. In 2001 he became regular research scientist in BI’s Structural Research group (Biberach, Germany), where he is using biophysical technologies and protein crystallography to support research discovery project teams. There, his experience spans a broad range of drug target families from enzymes, via integral membrane proteins to poorly druggable protein-protein complexes. Being collaborative by nature, he is representing BI research within several precompetitive consortia (GPCR consortium, SGC, EUbOPEN) and has in many cases succeeded to generate mutual value by collaborating with experts in the academic world. In 2019 he was appointed Innovation Facilitator, MedChem, where he is responsible for identifying novel technologies and synergies with internal and external partners. He is invited lecturer on protein crystallography and structure based design in drug discovery" and has been recognized with the Boehringer Research Award.
Prof. Jianfeng PEI
De Novo Drug Design Using 3D Deep Generative Models
UNIVERSITY OF MINNESOTA Minneapolis, United States
William C. K. Pomerantz, Associate Professor, University of Minnesota. Prof. Pomerantz received his B.S. in chemistry from Ithaca College in 2002, followed by a Fulbright Fellowship at ETH, Zurich with Professors François Diederich and Jack Dunitz. He obtained a Ph.D. in chemistry with Professors Sam Gellman and Nick Abbott at the University of Wisconsin-Madison and was a postdoctoral fellow with Prof. Anna Mapp at the University of Michigan. He joined the chemistry faculty at the University of Minnesota in 2012, and was granted tenure in 2018. He is currently the Merck Professor Chemistry. His research uses chemical biology and medicinal chemistry approaches for modulating protein-protein interactions involved in transcriptional complexes. Protein-Observed Fluorine NMR (PrOF NMR) is one such tool in his lab that is being developed as a new method for fragment-based ligand discovery (FBLD), and has been applied towards inhibiting a diverse class of epigenetic protein complexes. His research had been recognized through several awards including a Sidney Kimmel Cancer Scholar award, an NSF CAREER award, a Cottrell Scholar Award, and an International Chemical Biology Society (ICBS) Rising Star in Chemical Biology award Prof. Pomerantz is currently the global council co-chair for the ICBS, Vice Chair of the ACS Med. Chem. Lett Early Career Board, and councilor for the American Chemical Society.
Renaud joined Edelris in 2018 as the Head of Screening Technologies, where he pioneered the development of AS-MS technologies.
Prior to this, Renaud served as the Chief Operating Officer at Cellipse, a drug discovery start-up company that he co-founded.
During his post-doc time, Renaud developed and applied different screening approaches in the oncology area, for example synthetic lethality and drug enhancers.
He obtained a Ph.D. in chemical biology from the Université Grenoble Alpes, where he worked on the screening of allosteric kinase inhibitors.
He has co-authored over 25 publications and patents.
Dr Jean QUANCARD
Tipping the Balance: MALT1 Inhibitors with Paradoxical Effects on the Immune System
Jean Quancard studied Chemistry at Ecole Normale Superieure in Paris and continued with a PhD in Chemical Biology at University of Pierre et Marie Curie. In 2004, he moved to Stanford University in the US for a Postdoc with Pr. Barry Trost. Jean joined Global Discovery Chemistry at Novartis in 2006 and since then worked in several therapeutic areas such as autoimmunity, oncology, ophthalmology and neuroscience. Currently, he is Executive Director and Head of Chemistry for the Musculoskeletal disease area where he focuses on drug discovery for neuromuscular diseases, Osteoarthritis and tendon diseases. In addition, Jean is co-leading a global team focused on developing data and digital for discovery chemistry. Jean received several awards including the 2016 Outstanding young medicinal chemist in industry from the European Federation for Medicinal Chemistry (EFMC) and co-authored more than 35 publications and patents. Jean is also a visiting lecturer in Drug Design at EPFL in Lausanne and leads the working group on Best Practices in Medicinal Chemistry for the EFMC.
Dr. Rastinejad is Wellcome-Trust Senior Investigator and Professor of Biochemistry at the University of Oxford, and Senior Kurti Fellow of Brasenose College. He received dual Bachelor degrees from Northwestern University in Mathematics and Biochemistry, and a Ph.D. degree from the University of Pennsylvania in Biophysics. He further trained as a postdoctoral fellow with Paul Sigler at Yale University, where he began his interests in structural characterization of gene-regulatory complexes. His laboratory at Oxford currently studies structures and small-molecule binding properties of transcription factors that act as nutritional, hormonal, and environmental sensors. For his work on nuclear receptors and mammalian bHLH-PAS proteins, Dr. Rastinejad has received multiple career honors, including Glaxo Wellcome Chemistry Scholar award, Established Investigator award from the American Heart Association, and Fellow of Royal Society in Biology.
Prof. Andrea RENTMEISTER
Investigating and Controlling mRNAs Via Chemo-enzymatic Modification
Andrea Rentmeister is a Professor at the Department of Chemistry at the Westfälische Wilhelms-Universität Münster. She studied Chemistry at the Technical University of Graz and the University of Bonn, where she earned her PhD in 2007. After a postdoctoral stay at the California Institute of Technology, she started her independent career as a Junior Professor at the University of Hamburg in 2010. In 2013, Andrea was appointed as Associate Professor at the Westfälische Wilhelms-Universität Münster, and in 2020 promoted to Full Professor.
Research in her lab focuses on RNA at the interface of chemistry and biochemistry and aims to understand and ultimately control the processes affecting mRNA expression and turnover. Andrea received an Emmy Noether Fellowship, an ERC Consolidator and POC Grant and the Hoechst Award of the Aventis Foundation. She is a fellow of the Royal Society of Chemistry and serves on several advisory and executive boards.
Judith Maria Rollinger is Professor of Pharmacognosy/Pharmaceutical Biology and Head of ‘Phytochemistry and Biodiscovery’ at the Department of Pharmaceutical Sciences, Faculty of Life Science, University of Vienna, Austria. Since 2019 she is member of the senate of this University.
She received her Ph.D. in Pharmacognosy of the University of Innsbruck/Austria; for her venia docendi she was among the first to combine cheminformatics, phytochemistry, and ethnopharmacology (habilitation in 2007). She was appointed full Professor of Pharmacognosy/Pharmaceutical Biology at her present institution in 2014. Since 2020 she is the president of the “Society for Medicinal Plant and Natural Product Research”- the largest European learned society, focusing on research on natural products, nature-based drug discovery, medicinal plant research and quality control of herbal medicines.
Her research focuses on the interdisciplinary field of integrating big data analysis (chemoinformatics, chemometry) in natural product research as strategy for the discovery of natural lead structures for treating viral infections, metabolic syndrome and inflammation. Publications resulting from her research have appeared in highly ranked international journals (>120), and as book contributions and patents.
Dr Fanny ROUSSI
Design of Naturally Inspired Anti-Cancer Compounds that Modulate Cholesterol Homeostasis
Fanny Roussi is currently CNRS research director at the Institut de Chimie des Substances Naturelles (ICSN, France). She studied pharmacy and obtained a PhD in Medicinal Chemistry in 1999 in the group of Henri-Philippe Husson (Paris Descartes University, France). She then worked as a post-doctoral fellow in Jack Baldwin’s group at Oxford University (UK), on the biomimetic synthesis of a family of natural compounds. In 2001, she joined the ICSN as a CNRS researcher to work on the synthesis of natural bioactive compounds. Since 2013, she has been the team leader of the “Plant Metabolites” group, which aims to valorise secondary metabolites of therapeutic interest identified from the ICSN plant extract library. The main lines of research currently being developed in the team focus on the discovery of original antitumor agents and new anti-infectives.
Dr Jörg SCHEUERMANN
Innovating DNA-encoded Chemical Library Technology for Better Ligand Discovery
Jörg Scheuermann studied Chemistry at the University of Heidelberg (Germany) and at the ETH Zurich (Switzerland). During his Ph.D. studies at the ETH Zurich he worked on the identification of novel binding molecules to markers of angiogenesis. Since 2002, as a Postdoc, he developed DNA-encoded library (DEL) technology in different implementations together with Dario Neri, with whom he holds the publication record in the DEL field. JS wrote his habilitation thesis on "DNA-Encoded Chemical Library Technology for Drug Discovery” and he is co-founder and organizer of the “International Symposium on DNA-Encoded Chemical Libraries”, a yearly alternating event between ETH Zurich/Switzerland, Boston/US and China. JS is Principal Investigator at ETH Zurich, currently heading a group of 5 PhD students and 1 Postdoc. His main research interests are the development of novel DEL architectures, selection methodologies and the tailored construction of DELs for difficult targets.
Kristian Strømgaard is a Professor of chemical biology at the Center for Biopharmaceuticals, University of Copenhagen. He obtained an MSc degree in Chemical Research from University College London, and continued as a PhD student in medicinal chemistry, part-time at H. Lundbeck. He did a post doc at Columbia University (New York), and shortly after, he was appointed H. Lundbeck Professor at the age of 36 to establish research in Chemical Biology. He won the ‘Teacher of the Year’ award from the Faculty of Pharmaceutical Science (Univ. Cph.) in 2009. In 2012, he co-founded Avilex Pharma, where he has taken the lead compound into clinical development. In 2014, he was appointed Director of Center for Biopharmaceuticals, where he has headed a research center on peptide and protein engineering. Recently, he was visiting professor at Harvard Medical School (Boston) to explore medical research and innovation. In 2021 he was awarded the 2021 University of Copenhagen Innovation Award and appointed Novo Nordisk Foundation Distinguished Innovator.
Dr Nicolas THOMÄ
Haven't Got a Glue: Protein Surface Variation for the Design of Molecular Glue Degraders
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH Read more
Dr Nicolas THOMÄ
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH Basel, Switzerland
Prof. Guy VAN DEN MOOTER
Formulation Strategies for Compounds with Challenging Physicochemical Properties
Jarrod is currently an Associate Director in AstraZeneca’s Hit Discovery department with over 20 years’ experience in the pharmaceutical industry. He joined AstraZeneca’s High Throughput Screening (HTS) team in 2000 after graduating from the University of Liverpool with a degree in Genetics. During his career he’s remained aligned with early stage drug discovery and primarily hit identification working extensively with screening applications, assay development activities and biophysical technologies. Since 2012 Jarrod focused on devising approaches to identify and eliminate compounds functioning via undesirable mechanisms of action to improve the quality of hit to lead compounds. He now leads a team dedicated to applying biochemical and biophysical screening methodologies.
Prof. Daniel Martin WATTERSON
Beyond Amyloid and Tau: Exploring Alternative Therapeutic Targets Using an Integrative Approach
After a training in Chemistry at the University of Pisa, Italy, Paola B. Arimondo obtained a PhD in Biophysics at the MNHN, Paris, and a PhD in Chemistry at the Scuola Normale Superiore of Pisa. She is research director at the CNRS and head of the Epigenetic Biological Chemistry Unit and the Structural Biology and Chemistry Department of the Institut Pasteur and the CNRS-Institut Pasteur UMR 3523 Chem4Life dedicated to Chemistry for Life. Her research activities are focused on the epigenetic regulation and its targeting with chemical molecules to fight diseases. Her team designs molecules to reprogram cells by mdoulating the aberrant epigenetic landscapes induced by cancers and pathogens during infection. Because of her interest in the development of new drugs, before joining the Institut Pasteur, she directed the Epigenetic Targeting of Cancer (ETaC) unit, a joint public-private laboratory between the CNRS and Pierre Fabre Laboratories, in Toulouse, France.
Dr Giulia BERGONZINI
Visible-light Photocatalysis: a Powerful Tool in the Pursuit of New Pharmaceuticals
Giulia Bergonzini is currently an Associate Principal Scientist at Early CVRM Medicinal Chemistry R&D BioPharmaceuticals, AstraZeneca (Sweden) where she focuses on medicinal chemistry and synthetic organic chemistry with a special interest in visible-light photocatalysis and its application to medicinal chemistry projects.
Giulia obtained her BSc and MSc in chemistry from the University of Bologna (Italy) and her PhD in organic chemistry and catalysis at ICIQ-Institute of Chemical Research of Catalonia (Spain) in 2013 under the supervision of Prof. Paolo Melchiorre. She did a sabbatical at Boston University (USA) under the supervision of Prof. Corey Stephenson and carried out her postdoctoral research at Gothenburg University (Sweden) before joining GSK (UK) as a Process Development Chemist. In 2017 she begun her career at AstraZeneca (Sweden) as a Senior Research Scientist. Current academic collaborations include Prof. Burkhard König (University of Regensburg) and Prof. Belén Martín-Matute (Stockholm University).1,2
1 M. Schmalzbauer et al., Redox-neutral Photocatalytic C–H Carboxylation of Arenes and Styrenes with CO2. Chem 2020, 6, 2658-2672.
2 T. D. Svejstrup et al., Effects of Light Intensity and Reaction Temperature on Photoreactions in Commercial Photoreactors. ChemPhotoChem 2021, 5, 808-814.
Dr Virgyl CAMBERLEIN
Discovery of Pseudomonas Aeruginosa Elastase LasB Inhibitors by in Situ Click Chemistry
HIPS - HELMHOLTZ-INSTITUT FÜR PHARMAZEUTISCHE FORSCHUNG SAARLAND Read more
Dr Virgyl CAMBERLEIN
HIPS - HELMHOLTZ-INSTITUT FÜR PHARMAZEUTISCHE FORSCHUNG SAARLAND Saarbrücken, Germany
Virgyl Camberlein graduated from the School of Pharmacy in Lille (France) in 2018 and obtained his M.Sc. in Medicinal Chemistry the same year from the University of Lille. He carried out his Master’s research project, in the group of Prof. Dr. Deprez-Poulain (Lille, France), on the design and optimization of Hydroxamic Acid-Based Endoplasmic Reticulum Aminopeptidases (ERAP) inhibitors; the ERAP being zinc-metalloproteases involved in the immune response. Later on, in 2022, he received his Ph.D from the University of Lille and the Saarland University, focusing on the discovery of zinc-metalloproteases inhibitors through protein-templated reactions. He performed the first half of his Ph.D, under the supervision of Prof. Dr. Deprez-Poulain in Lille (France), focusing on the discovery of new ERAP inhibitors as immunomodulatory drugs, and the second half, under the supervision of Prof. Dr. Hirsch, focusing on the discovery of new Elastase LasB inhibitors as anti-infective drugs; LasB being a key actor in the virulence process of Pseudomonas aeruginosa. Currently, he continues as a postdoctoral researcher, in the group of Prof. Dr. Hirsch, with a focus on the design and synthesis of bacterial zinc metalloproteases inhibitors.
Dr Laura CARZANIGA
Discovery of Clinical Candidate CHF-6366: a Super-soft Heterobifunctional Muscarinic Antagonist and β2-adrenoceptor Agonist (MABA) for the Inhaled Treatment of Respiratory Diseases
Laura is a Principal Scientist at Chiesi Farmaceutici. After receiving her Master Degree in Medicinal Chemistry and Pharmaceutical Technology from the University of Milan in 2005 she moved to the pharmaceutical industry as a researcher at Nicox Research Institute first, where she worked on novel chemical entities with ophthalmic and anti-inflammatory applications, and at Chemo Pharma later, focussing on the route scouting of new chemical processes. She moved to Chiesi in 2010 joining the Medicinal Chemistry Unit. Her current research activities in the field of drug discovery are mainly devoted to the drug design, lead identification and optimization of novel small-molecules to target asthma, COPD, fibrosis and related respiratory disorders. She has been involved in several project teams contributing to the identification of pre-clinical and clinical candidates. Author of peer-reviewed scientific publications and co-inventor of 17 patents.
Prof. Christina CHAI
Tuning the Reactivity of the Natural Product Andrographolide: Towards Targeted Covalent Inhibitors for the Treatment of Inflammation
NATIONAL UNIVERSITY OF SINGAPORE Singapore, Singapore
Professor Christina Chai obtained her BSc (Hons) from the University of Canter¬bury, Christchurch, NZ and her PhD from the Australian National University, Canber¬ra. Following her PhD, she was awarded a Samuel and Violette Glasstone Research fellowship at University of Oxford, UK. This was followed by Faculty positions in Victoria University of Wellington, NZ and Aus¬tralian National University, then the Agency for Science Technology and Research (A*STAR), Singapore as Principal Sci¬entist. She joined the Department of Pharmacy, National University of Singapore in 2011 where she held roles as Deputy Head of Department and Assistant Dean in the Faculty of Science. She is currently the Head of the Department of Pharmacy since Jan 2016. Her research interest is broadly in the area of medicinal chemistry with special interests in natural products as lead compounds for drug development. Currently her research group is focussed on drug development for inflammation and infectious diseases.
Dr Bryan CHOI
Accelerating Drug Discovery with the Integration of Affinity Selection Mass Spectrometry (ALIS)
First Selective Nanomolar Inhibitors of ERAP2 for Modulation of the Antigen Presentation
UNIVERSITY OF LILLE / INSTITUT PASTEUR OF LILLE Read more
Prof. Rebecca DEPREZ-POULAIN
UNIVERSITY OF LILLE / INSTITUT PASTEUR OF LILLE Lille, France
Rebecca Deprez-Poulain, PharmD, is Professor of Medicinal Chemistry. She heads a group in the Drug discovery lab of the University of Lille focusing on the inhibition of metalloproteases for therapeutic uses. She is currently coordinating the European project CAPSTONE-ETN dedicated to ERAP modulation in immuno-oncology and autoimmune diseases. She has published more than 70 papers in international peer-reviewed journals, including J. Med. Chem, Nat. Comm, Nat. Med. and is the inventor of several patents. She completed her PhD under the supervision of Pr Tartar in combinatorial chemistry applied to drug discovery at CEREP.SA. After two postdoctoral positions, she was appointed Associate Professor in 2001, and then Professor in 2010 at the School of Pharmacy in Lille, France. She was nominated member of the Institut Universitaire de France in 2015 and has been the recipient of the SCT/Servier Research Encouragement Award (2009) and the Delalande Award in Pharmacochemistry of the Académie Nationale de Pharmacie (2020). She is currently the President of the French Society of Therapeutic Chemistry (2021-2022).
Richard is a Lecturer in Chemical Biology within the Leicester Institute of Structural and Chemical Biology and School of Chemistry at the University of Leicester, UK. His research is focussed on the application of chemical synthesis and chemical biology approaches for the development of novel pharmaceutical modalities. In particular, his group has a keen interest in the discovery, design and evaluation of molecular glues. Prior to joining the University of Leicester Richard held a Marie Curie fellowship at the Eindhoven University of Technology (NL) and undertook a post-doctoral research project at the University of Leeds (UK).
Prof. Karl GADEMANN
Reduce to the Max: Functionally Optimized Natural Products via Chemical Synthesis
Hervé Geneste earned his doctoral degree from the University of Lausanne (with Prof. M. Schlosser). After a postdoc at Zurich University, he joined BASF (drug discovery). He is now Principal Research Scientist and team leader (AbbVie, Germany) with 20+ years’ experience in medchem & neuroscience. Hervé has a proven track record up to clinical candidates: key contribution to ABT-614 (Ph1, dopamine D3 antagonist), ABT-436 (Ph2, V1b antagonist). He has served as target champion & co-leader of international project teams (schizophrenia, Alzheimer’s disease and multiple sclerosis). He is inventor of 61 published patents and author of 26 peer-reviewed articles or reviews. Hervé has a passion for new technologies, teaching (lecturer, Montpellier) and green chemistry. He has initiated a global effort investigating the potential of mechanochemistry for AbbVie portfolio products and he´s leading a cross-functional team aiming at in silico prediction of brain penetration (machine learning).
Dr Francesco GRECO
NR2F6 Antagonists: in Vitro Pharmacology and Preclinical Data of a Potential Next Generation Immuno-oncology Therapy
Thomas Hayhow began his chemistry career doing undergraduate studies at the University of York before joining GSK as a medicinal chemist. He spent almost 15 years across various sites and disease areas before eventually ending up at the Stevenage site in the epigenetics field focussing on developing treatments for immuno-inflammatory diseases. While working on drugging epigenetic targets he undertook a PhD in collaboration with the University of Strathclyde under the tutelage of Dr. Philip Humphreys and Prof. Colin Suckling. He joined AstraZeneca in 2016 as part of their Oncology Chemistry department and is an associate principle scientist concentrating on targets for protein degradation since 2017.
Dr Timo HEINRICH
Optimization of TEAD P-Site Binding Fragment Hit into In Vivo Active Lead MSC-4106
Founding Scientist, Vernalis and Emeritus Professor, University of York
Rod Hubbard has been working with methods for analysis and exploitation of protein structure for over 40 years. Apart from brief spells at Harvard (with Martin Karplus), he has spent his academic career at York. In the 1980s, he was a pioneer in the development of molecular graphics and modelling methods that were commercialized by Accelrys. In the 1990s, he collaborated with many pharmaceutical companies on the structure of important drug targets while developing new ideas in how to use structural information in drug discovery. Since 2001 he has divided his time between structure and fragment-based methods for chemical biology at York and innovation in drug discovery research at Vernalis, where his current main role is initiation and coordination of external research collaborations.
Dr Soufyan JERHAOUI
Discovery of JNJ-1245, a Novel and Potent Fluoroallylamide Mcl-1 Inhibitor for the Treatment of Hematologic Malignancies
Soufyan obtained his engineering diploma and master’s degree in chemistry from the University of Rennes in 2015. Then, he graduated Ph.D. in organic chemistry from the University of Strasbourg in 2018 under the supervision of Prof Colobert and Dr Djukic. During his Ph.D. studies, he used chiral sulfoxides moieties to develop new strategies for the asymmetric C(sp3)-H bond activation. Then, he joined Janssen in 2019 as Scientist in the Discovery Chemistry department. He initially worked in the oncology field where he assumed responsibility for a subseries in the MCL1 inhibitor program and more recently became Senior Scientist co-leading a project in the neuroscience space. He’s also involved in the CHAIR, a Marie Curie funded ITN project gathering leading R&D laboratories from academia and industry for which the main objectives are developing novel, safe and efficient C-H activation methods as well as training the next generation of organic chemists. Soufyan is co-author of 9 peer-reviewed papers and 2 patents.
Dr Manuela JORG
Identification and Structure-activity Relationship Profiling of Positive Allosteric Modulators Targeting Muscarinic Acetylcholine Receptors
Dr. Manuela Jörg is a Monash and Newcastle University Research Fellow who develops pharmacological tools and small-molecule drugs to support drug discovery research. She obtained a PhD in Medicinal Chemistry from Monash University, in addition to a Bachelor and Masters in Chemistry at the University of Applied Sciences Northwestern Switzerland and the University of Basel, respectively. Prior to her academic career, she completed an apprenticeship as a chemical lab-technician and has experience working in industrial and government organisations.
Dr Anna JUNKER
Development of First PET Tracers for the Imaging of CD73 Expression in Triple-negative Breast Cancer
EUROPEAN INSTITUTE FOR MOLECULAR IMAGING Read more
Dr Anna JUNKER
EUROPEAN INSTITUTE FOR MOLECULAR IMAGING Muenster, Germany
Ms Elizabeth A. LOPES
Dual Inhibition of P53-MDM2/4 Interactions With Spiropyrazoline Oxindoles
Elizabeth Lopes obtained her Bachelor's in chemistry from the University of Porto in 2014 and received her M. Sci. from the New University of Lisbon in 2017. Her M. Sci. project was developed at the Research Institute for Medicines (iMed.ULisboa) under the supervision of Prof. Maria M. M. Santos and was focused on the development of spirooxindole-based reactivators of the p53 protein. After the M. Sci., E. Lopes developed a project for Hovione Farmaciência SA. (Portugal) and in 2018, she started a PhD in Pharmacy at the University of Lisbon under the supervision of Prof. Maria M. M. Santos (University of Lisbon, Portugal) and Professors Maurizio Botta/Mattia Mori (University of Siena, Italy). Her PhD project focuses on in silico design, and synthesis of new p53 reactivators for evaluation of their effect on cancer and malaria and was already recognized by several prizes, and grants such as best poster award at 5th MC/WG Meeting Cost Action CM1407, best flash presentation award at Bio.Natural Meeting and Cost Action CM1407 STSM grant.
Ms Katherine MACFARLANE
Exploiting DNA-encoded Library Technology for the Discovery of Novel Antibody Recruiting Molecules Against LOX-1
Dr Exequiel Porta (EP) is a PhD in Chemical Sciences (Best GPA and best Argentinian thesis awarded), MSc in Biotechnology (1st class, Rosario National University, Argentina). In 2018 EP was granted the Durham International Junior Research Fellowship (COFUNDed between Durham University and the European Union - Marie Curie Actions) for a research position at Durham University (United Kingdom). EP's area of expertise includes medicinal chemistry, organic synthesis, biotechnology, bioinformatics, parasitology (particularly directed in neglected tropical diseases), and chemical biology. EP have generated a toolbox of Serine and Kinases activity- and affinity- based probes to identify and validate new drug targets in Leishmania spp to provide a general resource that will underpin efficient drug discovery programmes. EP is member of the Network for Neglected Tropical Diseases, the Royal Society of Chemistry, and the American Society of Chemistry (division of medicinal chemistry).
Dr Filipa RAMILO-GOMES
New Generation of EZH2 Inhibitors for Cancer Therapy: A Computer-Aided Drug Design Approach in Epigenetics
Stefano Sainas is Post-Doc of Medicinal Chemistry at the University of Torino. After the degree in Chemistry and Pharmaceutical Technology in 2013, he gained his PhD in the laboratory of Prof. Lolli in 2017. During the PhD, he joined the group of Prof. Frølund at University of Copenhagen, (Denmark) and of Prof. Guedes (Faculdade de Farmácia - Universidade de Lisboa) as visiting scientist. His research is focused on the field of drug discovery, bioisosterism, heterocyclic chemistry and fluorescent probes. He has recently co-founded Drug Discovery and Clinic s.r.l, a spin-off company committed to the development of DHODH inhibitors, for the treatment of cancer.
Dr Matthew SEGALL
Using AI to Derive Valuable Insights from Drug Discovery Data
Matthew Segall is CEO of Optibrium. He has an MSc in Computation from the University of Oxford and a PhD in theoretical physics from the University of Cambridge. Since 2001, Matthew has led teams developing predictive models and intuitive decision-support and visualization tools for drug discovery. Matt has published over 40 peer-reviewed papers and book chapters on computational chemistry, cheminformatics and drug discovery. In 2009 he led a management buyout of the StarDrop™ business to found Optibrium, which develops novel technologies and ground-breaking AI software and services, including Cerella™ and Inspyra™, that improve the efficiency and productivity of drug discovery.
Dr Alice SOSIC
Bis-3-chloropiperidines Targeting TAR RNA as a Novel Strategy to Impair the HIV-1 Nucleocapsid Protein
Alice Sosic is Assistant Professor at the Department of Pharmaceutical and Pharmacological Sciences at the University of Padova. She studied Pharmaceutical Chemistry and Technologies at the University of Padova, where she earned her PhD in Molecular Sciences in 2013. She is a medicinal chemist highly specialized in drug development and in the evaluation of drugs molecular mechanisms of action. Her research has been mainly focused on the study of Nucleic Acids, especially RNA, representing a valid target for new antiviral and anticancer agents. In 2016, she was awarded with a MSCA Individual Fellowship at The RNA Institute (SUNY Albany, NY, USA) that allowed her to obtain wide and distinctive expertise in the using of Mass Spectrometry for the investigation of RNA structures, structure-function relationships of RNA-ligands and RNA-protein complexes involved in the lifecycle of viruses.
Dr Léopold THABAULT
Interrogating Lactate Dehydrogenases Oligomeric Interfaces Using (Stapled) Peptides And Small Molecules
INSTITUTE OF CANCER RESEARCH London, United Kingdom
Dr Léopold Thabault obtained his master’s degree in pharmacy at the Université Catholique de Louvain (Belgium) in 2016. He was then granted an FNRS Research Fellow fellowship and started a doctorate in the laboratories of Pr. Raphaël Frédérick (Louvain Drug Research Institute) and Pr. Pierre Sonveaux (Institut de Recherche Expérimentale et Clinique). During his Ph.D., he studied lactate dehydrogenase and developed peptide tools capable of modulating its tetramerization process. After obtaining his doctoral degree in 2020, he joined the group of Dr. Max Douglas at the Institute of Cancer Research in London to work on cross-talks of heteromeric complexes involved in DNA replication. In September 2022, he will start a new position at Galàpagos (Mechelen, Belgium) as a scientist specialist in biophysics.
Dr Boris VAUZEILLES
Fast Detection and Imaging of Hydrogen Peroxide with New Borinic Probes
INSTITUT DE CHIMIE DES SUBSTANCES NATURELLES Read more
Dr Boris VAUZEILLES
INSTITUT DE CHIMIE DES SUBSTANCES NATURELLES Gif-sur-Yvette, France
Former student of the Ecole Normale Supérieure in Paris, Boris Vauzeilles prepared his PhD under the supervision of Prof. Pierre Sinaÿ in the Chemistry Department of this institution. He then joined Prof. Julius Rebek, Jr. at MIT (Cambridge, Massachussets), for a post-doctoral experience. The group soon moved to the Scripps Research Institute in La Jolla, where Julius Rebek was promoted as Director of the Skaggs Institute for Chemical Biology. Boris Vauzeilles then returned to France as a CNRS researcher (Institut de Chimie Moléculaire et des Matériaux d’Orsay, Université Paris-Saclay), and in 2012 he created, in parallel with his research in Orsay, a new team at the Institut de Chimie des Substances Naturelles in Gif-sur-Yvette, where he initiated in 2015 the Department of Chemical Biology. He is also the co-founder of a startup company, Diamidex, and was awarded, together with his group, the Prix La Recherche in 2015. His research is mainly focused on the use of synthetic chemistry to develop molecular tools designed to probe biological processes. Mainly educated as a synthetic glycochemist, he evolved towards the development of eco-friendly chemistry starting from biomass, design and synthesis of molecular devices for artificial photosynthetic systems for energy conversion, in vivo chemistry with the metabolic labeling of living bacterial lipopolysaccharides, and the development of new molecular probes for reactive oxygen species. Since early 2020, he is the Director of Institut de Chimie des Substances Naturelles (ICSN) and President of SCF-ChemBio, the new Chemical Biology Group from the French Chemical Society. SCF-ChemBio joined the European Federation for Medicinal chemistry and Chemical biology (EFMC).
Dr Anita WEGERT
A New Dual Mode of Action to Treat Pain - From Scratch to Pre-Clinical Candidate
As a Director Medicinal Chemistry at Symeres, I am currently responsible for the leading of 5 different customer-oriented drug discovery projects. These projects vary from Lead Finding to Lead Optimization with the aim to deliver a preclinical candidate and consist of 2-10 chemists, in total about 30 chemists. The projects vary in the targets and disease areas, covering pain, inflammation, cancer, and anti-infectives. Analyzing biological data, establishing structure activity relationships and structure property relationships belong to my daily work. I started my career in 2006 with a PhD in Organic Chemistry from the University of Rostock in Germany. After a PostDoc at DSM-Nutritional Products AG, Switzerland in Process Research and a PostDoc at Merck KGaA, Germany in the synthesis of fluorinated building blocks and natural product analogues, I joined in 2008 the Grünenthal GmbH, Germany as a Project lead and laboratory head Medicinal Chemistry. Since 2014 I am working for Symeres, former Mercachem.
Dr Erik WEIS
Iridium-catalyzed C-H Activation Methods for Late-stage Functionalization of Pharmaceuticals
Erik Weis received his B.Sc. in biochemistry from the Masaryk University, Czechia, and M.Sc. in chemistry from the University of Gothenburg, Sweden. After this he joined the group of Prof. Belén Martín-Matute in collaboration with Dr. Magnus Johansson at AstraZeneca Gothenburg, obtaining a PhD in organic chemistry in 2022. His PhD work focused on the development of C-H activation methodologies for late-stage functionalization of pharmaceuticals and application of high-throughput experimentation techniques. Erik currently holds a position as Senior Scientist in Medicinal Chemistry within Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D at AstraZeneca, Gothenburg, Sweden. His research interests are focused around drug discovery and high-throughput experimentation for reaction discovery and optimization.
Prof. Jukka WESTERMARCK
Protein Phosphatase 2A, a Druggable Tumor Suppressor for Cancer Therapy
Jukka Westermarck (MD, PhD) is a Professor of Cancer Biology at the Institute of Biomedicine, University of Turku and a Research Director in the Turku Bioscience Centre at University of Turku, Finland.
Westermarck earned his medical degree in 1996, and his PhD degree in 1998 from University of Turku. He was working as a postdoctoral fellow in the laboratory of Dirk Bohmann during 1999-2001 in the European Molecular Biology Laboratory in Heidelberg, Germany. After being appointed as Academy Fellow by the Academy of Finland, he established his own research group at Turku Centre for Biotechnology in 2002. 2009 he was appointed to his current positions at the university of Turku.
Professor Westermarck is one of the international leaders of the phosphatase field. The work of Westermarck laboratory focuses on role and regulation of phosphatases, particularly tumor suppressor protein phosphatase 2A (PP2A) in human cancers. Based on this work his group has identified several novel signaling principles how PP2A regulates cancer progression, as well as potential novel cancer therapy targets and diagnostic biomarkers.
Dr Birgit WILDING
Discovery of Novel Covalent, EGFR WT Sparing, HER2 Selective Inhibitors for the Treatment of Her2 Exon 20 Insertion Driven Tumours
Birgit Wilding is a Scientific Director in the Medicinal Chemistry Department at Boehringer Ingelheim in Vienna, Austria. Since joining Boehringer Ingelheim in 2018, Birgit has led and impacted several drug discovery programmes in oncology research, and successfully delivered development candidates.
Birgit obtained her PhD in organic synthesis and biocatalysis at Graz University of Technology, in collaboration with the Austrian Centre of Industrial Biocatalysis (acib), followed by a position as postdoctoral researcher at acib. She then moved to the CRUK Drug Discovery Unit at the Institute of Cancer Research in London, UK as Postdoctoral Fellow in Synthetic Medicinal Chemistry. As medicinal chemist, Birgit has worked across modalities, including small molecule reversible and covalent inhibitors, as well as degraders, in early as well as late-stage projects. At both, the Institute of Cancer Research and Boehringer Ingelheim, Birgit contributed to drug discovery programmes which resulted in compounds now investigated in clinical trials.
First Time Disclosures
Dr Sophie BERTRAND
Discovery and Optimisation of Potent, Slow-dissociating Inhaled PI4KB Inhibitors
Sophie joined GlaxoSmithKline Stevenage in 2006, following her graduation from École Supérieure de Chimie Physique Électronique in Lyon, France with a Masters degree in Chemical Sciences and Engineering. For the past 16 years, Sophie has worked on a variety of targets across multiple disease areas (anti-bacterial, CNS and respiratory diseases), from fragment-based drug discovery approaches all the way to late lead optimisation. In 2011, she entered the GSK/Strathclyde PhD programme under the supervision of Dr Craig Jamieson, from which she graduated in 2015. She led the PI4KB medicinal chemistry team that delivered a first in class inhaled clinical candidate for the prevention of rhinoviral-driven exacerbations in respiratory diseases. Currently, Sophie is a team leader in the Medicinal Chemistry department, where she is guiding medicinal chemistry efforts to discover clinical candidates.
Dr Kenneth GRANBERG
Discovery of AZD5462, an Oral Agonist of the Relaxin Family Peptide Receptor 1 (RXFP1) for the Treatment of Cardiorenal Disease
Kenneth received his PhD 1991 based on studies of preparative and mechanistic aspects of palladium catalyzed oxidations and nucleophilic substitution reactions at Uppsala University under prof Jan-Erling Bäckvall’s supervision and did a preDoc 1990 in prof Lanny Libeskind’s group at Emory University on quinone synthesis. He joined Hässle (Astra) in 1991 as an organic chemist in the gastrointestinal chemistry department and has since held positions as team and preclinical drug project leader at AstraZeneca. In his current role a principal scientist within the Early Cardiovascular Renal & Metabolism area in the BioPharmaceuticals R&D unit, focus is on driving synthesis and medicinal chemistry progress in drug projects towards candidate drug selection but also to support the selection of new cardiovascular drug projects and follow advances in chemical toxicology.
Dr Uwe GRETHER
First Disclosure of Cannabinoid Receptor Type 2 Agonist Rg7774 – An Innovative Oral Treatment for Diabetic Retinopathy
Uwe Grether received his Diploma degree in Chemistry at the University of Karlsruhe, Germany, where he subsequently earned his Ph.D. in Organic Chemistry with Professor Herbert Waldmann in 2000. After that, he joined Professor James D. White’s group at Oregon State University for his postdoctoral research. In 2001, Dr. Grether started at the Pharma Research and Early Development unit of F. Hoffmann-La Roche Ltd. in Basel, Switzerland. He has a long standing professional experience as project team leader in drug discovery and development reaching advanced stages up to phase 3 clinical trials with multiple new molecular entities. Dr. Grether has profound knowledge on different target classes, a broad variety of indications, chemical biology, and expertise in due diligences. He has led academic as well as industrial external collaborations and is an intrapreneur of novel technologies for project and platform applications. Dr. Grether is co-author of more than 140 patents, research publications and book chapters. His research interests include medicinal chemistry, late stage functionalization and chemical probes focusing on holistic approaches toward a clinical end-goal.
Dr Peter HAEBEL
Discovery of BI 456906, a Novel Long-acting GCG/GLP-1 Receptor Dual Agonist for the Treatment of Patients With Obesity
BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Read more
Dr Peter HAEBEL
BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Biberach Riss, Germany
Dr. Peter Haebel works on the discovery of peptide therapeutics in the cardiometabolic field at Boehringer Ingelheim, where he is senior project lead in the Medicinal Chemistry department.
Peter studied chemistry at the University of Freiburg and obtained a PhD in protein crystallography at the University of Auckland. After postdoc projects in structural biology and molecular modelling at the ETH Zurich and the University of Marburg, Peter moved into industry. He joined the chemoinformatics team of Boehringer Ingelheim in 2007 and was leading a computational chemistry team before taking up his new position in medicinal chemistry.
His research interests include therapeutic peptides and open innovation.
BOEHRINGER INGELHEIM PHARMA GMBH&CO. KG Ingelheim am Rhein, Germany
Roland Pfau studied chemistry in Mainz and Irvine (California), and got his PhD in the group of Prof. Horst Kunz (Mainz) working in the field of carbohydrate chemistry.
He joined Boehringer Ingelheim 2002 as Labhead, advancing to Research Project Leader in 2005 and now fills a position as Senior Project Leader in CNS.
His research experiences and interests within CNS cover pain research, neurodegenerative diseases and psychiatric indications.
He contributed to 6 candidates entering development, 2 of which are currently pursued in clinical stages.
Here, the research story of the collaboration project with Gesyntha in Sweden behind the current clinical mPGES1 inhibitor BI01029539 will be presented, including first time disclosure of its structure.
Dr Kai SCHIEMANN
First-time Disclosure of M1069, a Highly Selective Dual Inhibitor of Adenosine A2a/A2b Receptors With Improved Therapeutic Activity Compared to A2a Receptor Selective Antagonists
Dr. Kai Schiemann is Principal Scientist in the Department of Medicinal Chemistry at Merck Healthcare KGaA, Darmstadt, Germany. He studied chemistry at the university of Göttingen and received his PhD in Organic Chemistry under the supervision of Professor Tietze in 1995. Prior to moving into drug discovery at Merck in Darmstadt in 1999, he completed postdoctoral studies on natural product synthesis at the University of Santa Cruz (Prof. Konopelski) and joined Parke Davis, division of Warner Lambert (now part of Pfizer) for 2 years in Ann Arbor Michigan in the MedChem and Combinatorial chemistry departments.
Over the past years his research has focused on the identification and development of small molecules on various target classes in oncology and immuno-oncology. In the discovery of M1069, which entered clinical phase I in 2022, he was co-project leader also leading the design and optimization of the clinical candidate in the preclinical phase.
• 28 publications (incl. lectures and posters)
• 78 patents
25 years of experience in drug research
EFMC Prizes for Young Medicinal Chemist or Chemical Biologist in Academia and in Industry Ceremony & Lectures